

Cystic Fibrosis Research News

Journal of

Cystic Fibrosis

The Official Journal of the European Cystic Fibrosis Society

Title:

Use of elexacaftor/tezacaftor/ivacaftor in liver transplant patients with cystic fibrosis

Lay Title:

Use of elexacaftor/tezacaftor/ivacaftor in liver transplant patients with cystic fibrosis

Authors:

Cameron J. McKinzie, PharmD, BCPPS, BCPS, CPP¹; Christina T. Doligalski, PharmD, BCPS, CPP¹; Steven J. Lobritto, MD²; Raymond D. Coakley, MD³; W. Adam Gower, MD⁴

Affiliations:

¹Department of Pharmacy, University of North Carolina Medical Center, Chapel Hill, NC ²Center for Liver Disease and Transplantation, Columbia University, New York, NY ³Marsico Lung Institute, University of North Carolina at Chapel Hill, Chapel Hill, NC ⁴Division of Pediatric Pulmonology, Department of Pediatrics, University of North Carolina School of Medicine, Chapel Hill, NC

What was your research question?

What are the effects of elexcaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) in two patients with history of liver transplant?

Why is this important?

ELX/TEZ/IVA has potential for clinical benefits for patients with cystic fibrosis, but it was not previously studied in patients with a history of liver transplant. Since it has potential side effects that affect the liver, it is important to work to understand more about how that might impact transplant patients.

What did you do?

Two patients with cystic fibrosis and history of liver transplant received ELX/TEZ/IVA.

What did you find?

Both patients experienced clinical benefits after starting ELX/TEZ/IVA, including improvement in lung function and nutritional status. Both also had delayed events related to liver function, but it is unclear whether they were related to ELX/TEZ/IVA.

Cystic Fibrosis Research News

cfresearchnews@gmail.com





Cystic Fibrosis Research News

What does this mean and reasons for caution?

This is the first published report of experience with giving ELX/TEZ/IVA to patients who have previously had a liver transplant, but only describes a small number of patients.

What's next?

Additional reports of patients with a history of transplant would continue to add to the published literature and provide more experience in this patient population.

Original manuscript citation in PubMed

https://pubmed.ncbi.nlm.nih.gov/34384711/

Cystic Fibrosis Research News

cfresearchnews@gmail.com